Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

McEwan, Phil, Poole, Chris D., Tetlow, Tony, Holmes, Paul and Currie, Craig John 2007. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23 (s1) , S21-S31. 10.1185/030079907X167570

Full text not available from this repository.

Abstract

Background: People with type 2 diabetes typically require insulin treatment following failure on hypoglycaemic agents. The purpose of this study was to evaluate the relative cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Insulin glargine has been shown to reduce the likelihood of hypoglycaemia and improve HbA1c in type 2 diabetes by comparison with NPH insulin. Methods: The study used a discrete event simulation model designed to forecast the costs and health outcome of a cohort of 1000 subjects over 40 years. The two main scenarios involved a difference in the likelihood of hypoglycaemia or a difference in HbA1c. Prices were in UK£ 2005 costs. Costs and benefits were discounted at 3.5% per year. Effectiveness data were pooled data from randomised clinical trials. Results: The incremental cost–effectiveness ratio of insulin glargine versus NPH insulin was £10 027 per quality adjusted life year under a differential hypoglycaemia-only scenario. The incremental cost–effectiveness ratio of insulin glargine versus NPH insulin was £13 921 per quality adjusted life year under a differential HbA1c-only scenario. In wide-ranging sensitivity analysis, the ICER was consistently below £20 000 per quality adjusted life year gained. Conclusion: This study was the first to evaluate the relative cost-effectiveness of insulin glargine versus NPH insulin. Insulin glargine resulted in significant health benefits and represents excellent value for money for the treatment of type 2 diabetes in the UK.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Cost, Economic, Effectiveness, Hypoglycaemia, Insulin glargine, NPH insulin, Type 2 diabetes
Publisher: Informa Healthcare
ISSN: 0300-7995
Last Modified: 04 Jun 2017 06:37
URI: http://orca.cf.ac.uk/id/eprint/62806

Citation Data

Cited 24 times in Google Scholar. View in Google Scholar

Cited 21 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item